Datavant and Prognos collaborate for a ‘more comprehensive view of the patient’

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: Data, data analysis, Data management, analytical, analytics, Clinical research, Clinical data, Clinical data management

Datavant enters partnership with Prognos to expand the latter’s analytics capabilities to determine clinical outcomes and inform decision making as data availability grows.

Through the partnership, Prognos, a company focused on providing analytics for disease prediction, will tap Datavant’s data ecosystem to expand its data and analytics, for its customers to make informed clinical decisions and identify any potential risks.

Datavant’s technology used in this agreement has been specifically designed to allow data sharing while still protecting patient privacy. This collaboration will also see Datavant’s data ecosystem grow, as Prognos’ existing data source partners and customers will be given the option to connect information to the company’s system.

A spokesperson for Datavant told us that Prognos’ product “only becomes more powerful when [it] can draw on data from additional sources. By replacing Prognos’ existing de-identification and linking the solution with Datavant’s, Prognos has the ability to form additional source relationships and integrate that data with what they already have.”

Using this analytical platform from Datavant, Prognos will be able to determine and predict trends in disease progression and provide health care companies with clinical insights to go alongside traditional medical claims.  

According to Sundeep Bhan, CEO and co-founder of Prognos, the analytical capabilities created from this agreement will give its customers “a more comprehensive view of the patient”​ and will enable more forward-looking insights to improve decision-making.

Bhan added, “As the amount of health care data exponentially increases, so does our potential for predicting disease and its trajectory, which enables us to get the right treatment and care to the right patient, at the right time.”

Currently, Prognos’ registry of laboratory results contains 24bn records covering 200m patients across more than 50 diseases. The company also has 1,000 proprietary clinical algorithms for patient identification and treatment decision making, risk management, and quality improvement.

Per the agreement, Datavant will also acquire Prognos’ OPAL product, a de-identification solution for diagnostic data. Users of the product will be migrated onto Datavant’s ecosystem and will have access to the company’s partners.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars